NIPPON KINZOKU “Eco-Product” Series - Vol. 2, Introducing “NK-301ZF”: A Breakthrough Material Combining High Strength and High Ductility
27.5.2025 02:01:00 CEST | Business Wire | Press Release
NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) is proud to introduce “NK-301ZF”, spring-use stainless steel that achieves both excellent processability and high strength within the chemical composition range of SUS301 (JIS), as part of its environmentally conscious “Eco-Product” series. This material has been widely adopted in various industries, including the automotive, electronic components, and semiconductors sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250526260185/en/
NK-301ZF combines high strength with high ductility, enabling both weight reduction of parts and simplification of manufacturing processes. These characteristics have led to its adoption in a wide range of applications, including smartphone components, diaphragm, and flat spiral spring.
NK-301ZF combines high strength with high ductility, enabling both weight reduction of parts and simplification of manufacturing processes. This contributes to improved energy efficiency and reduced environmental impact throughout the customer's entire manufacturing process. Additionally, its enhanced design flexibility allows for optimization of shapes and specifications, leading to improved processing efficiency and yield. These characteristics have led to its adoption in a wide range of applications.
At our company, NK-301ZF is designated as an “Eco-Product” based on these considerations. We are committed to sustainable manufacturing through the promotion of environmentally friendly materials, with the goal of achieving Net Zero CO₂ emissions by 2050.
This product was developed in accordance with NIPPON KINZOKU's 11th business plan, “NIPPON KINZOKU 2030”, which is focused on the key concept of “Near Net Performance" -achieving the performance required by end products through material design. Our objective is to further expand its sales in the automotive, electronic components, semiconductors, and related markets.
Features
1. Chemical Composition
The chemical composition is adjusted to meet the JIS standard range.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Chemical-Composition.pdf
2. Mechanical Property
Compared to conventional SUS301, NK-301ZF has greater elongation, helping to prevent cracking during forming. It is also a high-strength material that can achieve a hardness level of HV580 or higher.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Mechanical-Properties.pdf
At equivalent strength levels, it offers higher elongation and superior ductility to conventional SUS301.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Relationship-Between-Hardness-and-Elongation.pdf
3. Fatigue Resistance, Processability
We controlled the inclusions in the steel, which significantly reduced the amount of macroscopic nonmetallic inclusions.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Image-of-Inclusions.pdf
Consequently, we anticipate improved fatigue resistance.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/MIT-test-results.pdf
Click here for the full text.
https://www.nipponkinzoku.co.jp/assets/images/2025/05/Introducing-NK-301ZF-A-Breakthrough-Material-Combining-High-Strength-and-High-Ductility.pdf
About NIPPON KINZOKU Group
Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526260185/en/
Contacts
Production Process & Support Dept.
NIPPON KINZOKU CO., LTD.
Email: sisaku-sc@nipponkinzoku.co.jp
https://www.nipponkinzoku.co.jp/en/inquiry -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nipponkinz
oku.co.jp%2Fen%2Finquiry&esheet=54258926&newsitemid=20250526260185&lan=en-US&anc
hor=https%3A%2F%2Fwww.nipponkinzoku.co.jp%2Fen%2Finquiry&index=8&md5=1d8570ab32e
196c1177f7edf4aee24de
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom